Interventional Cardiology Devices Market to Grow from USD 31.12 Billion in 2026 to USD 42.39 Billion by 2031, at a CAGR of 6.4%

Delray Beach, FL, Aug. 25, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global interventional cardiology devices market will grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a CAGR of 6.4% during the forecast period. Market growth is driven by the rising worldwide prevalence of cardiovascular diseases, including coronary artery disease and structural heart disorders, linked to population aging, sedentary lifestyles, and increasing rates of diabetes and obesity. The growing preference for minimally invasive, catheter-based procedures over conventional open-heart surgery is further accelerating device adoption, supported by shorter hospital stays, faster recovery, and lower procedural risk.

Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=548

Key Market Highlights

Market size, 2026: USD 31.12 billion
Market forecast, 2031: USD 42.39 billion
Growth rate: CAGR of 6.4% (2026–2031)
Largest angioplasty stent segment: Drug-eluting stents (DES)
Largest catheter segment: Angiography catheters
Fastest-growing catheter segment: IVUS/OCT catheters
Largest structural heart devices segment: Other therapy devices
Largest end-user segment: Hospitals
Fastest-growing end-user segment: Ambulatory surgery centers
Largest regional market: North America
Key players: Boston Scientific Corporation (US), Medtronic (US), Abbott (US), Edwards Lifesciences Corporation (US), Terumo Corporation (Japan), B. Braun SE (Germany), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Asahi Intecc Co., Ltd. (Japan), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), Endocor GmbH (Germany), InSitu Technologies Inc. (US), Cardionovum GmbH (Germany), Medinol (Israel), and Balton (UK).

Why This Market Matters

The rising global burden of cardiovascular diseases is a major factor driving the interventional cardiology devices market. Conditions such as coronary artery disease, peripheral artery disease, and structural heart disorders are increasingly prevalent among aging populations and people affected by obesity, diabetes, and hypertension. The resulting demand for diagnostic angiography and interventional procedures is supporting the adoption of advanced catheter-based therapies for high-risk and elderly patients.

The clinical shift from open-heart surgery toward minimally invasive, catheter-based interventions is further accelerating market adoption. These procedures offer benefits such as shorter hospital stays, faster recovery, and lower complication rates. Next-generation drug-eluting stents, transcatheter heart valves, intravascular imaging, and physiology-guided diagnostics are expanding the range of conditions that can be treated through minimally invasive approaches.

Market Overview

The interventional cardiology devices market is undergoing significant technological transformation. Intravascular imaging technologies such as IVUS and OCT, along with pressure-based diagnostics including fractional flow reserve (FFR), are improving procedural accuracy and expanding access to complex PCI and structural heart interventions. These technologies improve diagnostic accuracy and procedural decision-making while helping reduce unnecessary interventions and repeat procedures.

The strong shift toward transradial access is also driving innovation in smaller-profile catheters, guidewires, stents, and vascular closure devices. Patient benefits, faster recovery, and lower overall costs are supporting this transition and aligning interventional cardiology with value-based care models.

Analyst Perspective

The migration of selected interventional cardiology procedures to outpatient and ambulatory care settings in developed markets represents an important opportunity for market players. At the same time, the expansion of catheterization lab capacity in emerging economies is creating additional demand for efficient and cost-effective interventional devices.

The transformation of catheterization laboratories into AI-enabled digital environments is another major growth opportunity. AI-enabled imaging, workflow automation, and data-driven clinical decision support are increasingly being integrated into cath-lab workflows, supporting procedural efficiency and evidence-based decision-making.

However, procedure-related complications remain a restraint for the market. Procedures such as TAVR, PCI, atherectomy, and chronic total occlusion interventions can involve risks including stroke, vascular complications, bleeding, arrhythmias, and repeat procedures.

Speak to Our Analyst - Get Custom Insights: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=548

Segment Analysis

By angioplasty stent type, drug-eluting stents (DES) are the fastest-growing segment and represent the standard of care in most PCI procedures. Their proven ability to reduce restenosis and repeat revascularization, along with ongoing innovation in struts, polymers, and bioresorbable materials, is supporting their use in increasingly complex lesions.

By catheter type, angiography catheters hold the largest share, supported by rising diagnostic and interventional procedure volumes. Meanwhile, IVUS/OCT catheters are growing at the fastest rate as intravascular imaging becomes increasingly important for precise and evidence-based PCI.

By structural heart devices, other therapy devices account for the largest share. This reflects the expanding range of transcatheter interventions beyond valve replacement, including left atrial appendage closure, supported by accumulating clinical evidence.

By end user, hospitals account for the largest share, supported by high procedure volumes and established catheterization laboratory infrastructure. Ambulatory surgery centers are the fastest-growing end user, as selected low- to moderate-risk procedures increasingly shift toward outpatient settings.

Regional Analysis

North America dominates the interventional cardiology devices market. The region benefits from a high cardiovascular disease burden, advanced catheterization-lab infrastructure, favorable reimbursement, rapid adoption of new technologies, and the presence of leading manufacturers with strong R&D pipelines. Rising volumes of complex coronary and structural heart interventions and increasing use of AI-powered imaging and navigation tools further reinforce the region's leadership.

Emerging markets, particularly in Asia Pacific, Latin America, and the Middle East, are expected to provide substantial growth opportunities. Rapid urbanization, improving healthcare infrastructure, increased healthcare spending, and rising cardiovascular disease prevalence are supporting greater adoption of cardiovascular interventions in these regions.

Key Industry Trends

Rising global burden of cardiovascular diseases
Increasing preference for minimally invasive, catheter-based interventions
Growing adoption of next-generation drug-eluting stents
Increasing use of transcatheter heart valves
Rapid adoption of intravascular imaging technologies
Growing use of IVUS and OCT
Increasing adoption of physiology-guided diagnostics
Strong shift toward transradial access
Development of smaller-profile interventional devices
Migration of selected procedures to ambulatory care settings
Expansion of catheterization lab capacity in emerging economies
Transformation of cath labs into AI-enabled digital environments
Increasing use of workflow automation and data-driven clinical decision support
Growing adoption of calcium-modification and structural heart technologies.

Competitive Landscape

The interventional cardiology devices market remained consolidated in 2025, with Boston Scientific Corporation, Medtronic, Abbott, Edwards Lifesciences Corporation, and Terumo Corporation collectively accounting for approximately 64–68% of the market. As healthcare systems increasingly focus on minimally invasive care, procedural precision, and value-based outcomes, manufacturers are accelerating innovation across next-generation stents, intravascular imaging, physiology-guided diagnostics, structural heart devices, and calcium-modification technologies.

Leading players offer comprehensive portfolios spanning coronary, peripheral, and structural heart interventions, including drug-eluting stents, angioplasty and drug-coated balloons, guidewires, atherectomy and intravascular lithotripsy systems, intravascular imaging, physiology-guided diagnostics, and structural heart solutions.

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Interventional Cardiology Devices Market to Grow from USD 31.12 Billion in 2026 to USD 42.39 Billion by 2031, at a CAGR of 6.4% – MarketsandMarkets™